Literature DB >> 23402554

Potential bias in medication adherence studies of prevalent users.

Matthew L Maciejewski1, Chris L Bryson, Virginia Wang, Mark Perkins, Chuan-Fen Liu.   

Abstract

PURPOSE: We examined how the choice of historic medication use criteria for identifying prevalent users may bias estimated adherence changes associated with a medication copayment increase.
METHODS: From pharmacy claims data in a retrospective cohort study, we identified 6,383 prevalent users of oral diabetes medications from four VA Medical Centers. Patients were included in this prevalent cohort if they had one fill both 3 months prior and 4-12 months prior to the index date, defined as the month in which medication copayments increased. To determine whether these historic medication use criteria introduced bias in the estimated response to a $5 medication copayment increase, we compared adherence trends from cohorts defined from different medication use criteria and from different index dates of copayment change. In an attempt to validate the prior observation of an upward trend in adherence prior to the date of the policy change, we replicated time series analyses varying the index dates prior to and following the date of the policy change, hypothesizing that the trend line associated with the policy change would differ from the trend lines that were not.
RESULTS: Medication adherence trends differed when different medication use criteria were applied. Contrary to our expectations, similar adherence trends were observed when the same medication use criteria were applied at index dates when no copayment changes occurred.
CONCLUSION: To avoid introducing bias due to study design in outcomes assessments of medication policy changes, historic medication use inclusion criteria must be chosen carefully when constructing cohorts of prevalent users. Furthermore, while pharmacy data have enormous potential for population research and monitoring, there may be inherent logical flaws that limit cohort identification solely through administrative pharmacy records. © Health Research and Educational Trust.

Entities:  

Keywords:  Medication adherence; cost sharing; inclusion criteria; pharmaceutical policy; research design; veterans

Mesh:

Substances:

Year:  2013        PMID: 23402554      PMCID: PMC3725535          DOI: 10.1111/1475-6773.12043

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  21 in total

1.  Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance.

Authors:  Lucie Blais; Julie Couture; Elham Rahme; Jacques LeLorier
Journal:  Health Policy       Date:  2003-05       Impact factor: 2.980

2.  Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.

Authors:  Lisa M Hess; Marsha A Raebel; Douglas A Conner; Daniel C Malone
Journal:  Ann Pharmacother       Date:  2006 Jul-Aug       Impact factor: 3.154

3.  A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp).

Authors:  Chris L Bryson; David H Au; Bessie Young; Mary B McDonell; Stephan D Fihn
Journal:  Med Care       Date:  2007-06       Impact factor: 2.983

4.  Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands.

Authors:  Helga Gardarsdottir; Eibert R Heerdink; Antoine C G Egberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-05       Impact factor: 2.890

5.  The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims.

Authors:  J X Zhang; T J Iwashyna; N A Christakis
Journal:  Med Care       Date:  1999-11       Impact factor: 2.983

6.  Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Alexander M Walker
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

7.  Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.

Authors:  Troy K Trygstad; Richard A Hansen; Steven E Wegner
Journal:  J Manag Care Pharm       Date:  2006-03

8.  Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization.

Authors:  Bessie Ann Young; Elizabeth Lin; Michael Von Korff; Greg Simon; Paul Ciechanowski; Evette J Ludman; Siobhan Everson-Stewart; Leslie Kinder; Malia Oliver; Edward J Boyko; Wayne J Katon
Journal:  Am J Manag Care       Date:  2008-01       Impact factor: 2.229

9.  The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.

Authors:  Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander
Journal:  Ann Intern Med       Date:  2008-01-07       Impact factor: 25.391

Review 10.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Authors:  Dana P Goldman; Geoffrey F Joyce; Yuhui Zheng
Journal:  JAMA       Date:  2007-07-04       Impact factor: 56.272

View more
  5 in total

1.  Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.

Authors:  Andrew W Roberts; Stacie B Dusetzina; Joel F Farley
Journal:  J Comp Eff Res       Date:  2015-01       Impact factor: 1.744

2.  Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.

Authors:  Qian Li; Abhishek Chitnis; Mette Hammer; Jakob Langer
Journal:  Diabetes Ther       Date:  2014-09-26       Impact factor: 2.945

3.  Medication adherence among patients with Type 2 diabetes: A mixed methods study.

Authors:  Nouf M Aloudah; Neil W Scott; Hisham S Aljadhey; Vera Araujo-Soares; Khalid A Alrubeaan; Margaret C Watson
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

4.  Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis.

Authors:  Clara L Rodríguez-Bernal; Aníbal García-Sempere; Isabel Hurtado; Yared Santa-Ana; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal:  BMJ Open       Date:  2018-12-19       Impact factor: 2.692

5.  Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.

Authors:  Qian Li; Rahul Ganguly; Michael L Ganz; Cory Gamble; Tam Dang-Tan
Journal:  Diabetes Ther       Date:  2018-05-09       Impact factor: 2.945

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.